Califf: ‘Enormous’ implications for FDA if user fee programs are not reauthorized
Regulatory NewsMichael Mezher
Biologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsMedical DevicesNorth AmericaPharmaceuticalsProduct LifecycleRegulatory Intelligence/Policy